A Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of VP1 Lido US for Volume Augmentation of the Cheek

NCT ID: NCT04886232

Last Updated: 2023-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

202 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-25

Study Completion Date

2023-05-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to demonstrate non-inferiority of VP1 Lido US versus an approved hyaluronic acid dermal filler following deep (subdermal and/or supraperiosteal) injection of the cheek for volume augmentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cheek Volume Augmentation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VP1 Lido US - NC

Injection to the left cheek via needle and to the right cheek via canula

Group Type EXPERIMENTAL

VP1 Lido US

Intervention Type DEVICE

Hyaluronic acid dermal filler containing lidocaine

VP1 Lido US - CN

Injection to the left cheek via canula and to the right cheek via needle

Group Type EXPERIMENTAL

VP1 Lido US

Intervention Type DEVICE

Hyaluronic acid dermal filler containing lidocaine

Restylane Lyft Lidocaine - NC

Injection to the left cheek via needle and to the right cheek via canula

Group Type ACTIVE_COMPARATOR

Restylane Lyft Lidocaine

Intervention Type DEVICE

Hyaluronic acid dermal filler containing lidocaine

Restylane Lyft Lidocaine - CN

Injection to the left cheek via canula and to the right cheek via needle

Group Type ACTIVE_COMPARATOR

Restylane Lyft Lidocaine

Intervention Type DEVICE

Hyaluronic acid dermal filler containing lidocaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VP1 Lido US

Hyaluronic acid dermal filler containing lidocaine

Intervention Type DEVICE

Restylane Lyft Lidocaine

Hyaluronic acid dermal filler containing lidocaine

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a symmetrical rating of 2 (moderate) or 3 (severe) for right and left cheek on the Merz Cheeks Fullness Assessment Scale (MCFAS)
* Desires cheek augmentation to correct volume deficit in the midface and is willing to receive sufficient volume to achieve at least a 1-point improvement on the MCFAS

Exclusion Criteria

* Skin or fat atrophy in the midfacial region other than that related to age.
* Subjects with body mass index of \<18.5 or ≥30
* Acute inflammatory process or active infection at the injection site (e.g., acne, eczema, streptococcus infections), or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of AEs.
* Prior surgery, including midfacial plastic surgery, or has a permanent implant or graft in the midfacial region that could interfere with effectiveness assessments.
* Received midfacial region treatments with porcine-based collagen fillers or with RADIESSE® or with volumizing hyaluronic acid fillers such as but not limited to Juvéderm® Voluma, Restylane® Lyft within the past 24 months and/or with other HA fillers or mesotherapy within the past 12 months or plans to receive such treatments during participation in the study.
* Received facial dermal therapies (i.e., facial ablative or fractional laser, dermabrasion, chemical peels, non-invasive skin-tightening \[e.g., Ultherapy®, Thermage®\] and surgical procedures) in the midfacial region within the past 12 months or plans to receive them in the facial region during participation in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merz North America, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Merz Medical Expert

Role: STUDY_DIRECTOR

Merz Pharmaceuticals GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hautmedizin Bad Soden, Merz Investigational Site #0490189

Bad Soden am Taunus, , Germany

Site Status

Rosenparkklinik, Merz Investigational Site #0490099

Darmstadt, , Germany

Site Status

Praxis für Hautkrankheiten, Merz Investigational Site #0490375

Drensteinfurt, , Germany

Site Status

Dermatologic Private Practive, Merz Investigational Site #0490381

Düsseldorf, , Germany

Site Status

Universität Hamburg, Merz Investigational Site #0490095

Hamburg, , Germany

Site Status

Dermatologic Private Practice, Merz Investigational Site #0490345

Hamburg, , Germany

Site Status

Private Clinic, Merz Investigational Site #0490284

Mannheim, , Germany

Site Status

Privatpraxis für Dermatologie und Ästhetik, Merz Investigational Site #0490371

München, , Germany

Site Status

Haut- und Lasercentrum Potsdam, Merz Investigational Site #0490362

Potsdam, , Germany

Site Status

Centroderm GmbH, Merz Investigational Site #0490367

Wuppertal, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M930061001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.